|Support type:||Scholarships in Brazil - Scientific Initiation|
|Effective date (Start):||January 01, 2014|
|Effective date (End):||December 31, 2014|
|Field of knowledge:||Biological Sciences - Microbiology - Applied Microbiology|
|Principal researcher:||Eliane Namie Miyaji|
|Grantee:||Tiphanie Kertischka Lemos|
|Home Institution:||Instituto Butantan. Secretaria da Saúde (São Paulo - Estado). São Paulo , SP, Brazil|
Streptococcus pneumoniae is an important human pathogen, causing severe diseases such as meningitis, pneumonia, bacteremia and sepsis. The currently avaliable vaccines induce anti-capsular polysaccharide antibodies and have some disadvantages, such as limited serotype coverage and high production costs. The widespread use of the 7-valent conjugate polysaccharide vaccine led to a drastic reduction of infections caused by vaccine-serotypes, but there was also a rapid substitution with disease caused by non-vaccine serotypes. The development of alternative vaccines is thus still a priority and new strategies include the development of vaccines based on protein atigens. Among the most promising proteins is PspA(Pneumococcal surface protein A). This project aims at mapping epitopes recognized by monoclonal antibodies generated against PspA. A random peptide comercial library will be screened with the monoclonals. The determination of these epitopes opens up the possibility of using a recombinant protein containing several epitopes of PspA, that could induce broadly reactive antibodies and afford protection against different pneumococcal isolates.